Development of canagliflozin nanocrystals sublingual tablets in the presence of sodium caprate permeability enhancer: formulation optimization, characterization, in-vitro, in silico, and in-vivo study

Development of canagliflozin nanocrystals sublingual tablets in the presence of sodium caprate permeability enhancer: formulation optimization, characterization, in-vitro, in silico, and in-vivo study

AbstractCanagliflozin (CFZ) is a sodium-glucose cotransporter-2 inhibitor (SGLT2) that lowers albuminuria in type-2 diabetic patients, cardiovascular, kidney, and liver disease. CFZ is classified as class IV in the Biopharmaceutical Classification System (BCS) and is characterized by low permeabilit...

Full description

Bibliographic Details
Main Authors: Sammar Fathy Elhabal, Mohamed A El-Nabarawi, Nashwa Abdelaal, Mohamed Fathi Mohamed Elrefai, Shrouk A. Ghaffar, Mohamed Mansour Khalifa, Passant M. Mohie, Dania S. Waggas, Ahmed Mohsen Elsaid Hamdan, Samar Zuhair Alshawwa, Essa M. Saied, Nahla A. Elzohairy, Tayseer Elnawawy, Rania A. Gad, Nehal Elfar, Hanaa Mohammed, Mohammad Ahmad Khasawneh
Format: Article
Language:English
Published: Taylor & Francis Group 2023-12-01
Series:Drug Delivery
Subjects:
Canagliflozin (CFZ)
sublingual
nanocrystal
sodium-glucose cotransporter-2 inhibitor (SGLT2)
diabetes mellitus (type II)
streptozotocin
Online Access:https://www.tandfonline.com/doi/10.1080/10717544.2023.2241665

Internet

https://www.tandfonline.com/doi/10.1080/10717544.2023.2241665

Similar Items